inotuzumab
pfizer,ucb
['inotuzumab']
1/6 phase ii study of inotuzumab ozogamicin for the treatment of mrd-positive b-cell all n=20 (12 ph+, 8 ph-); mrd+ b-all. mfu=15 mos
mrd-ve responses= 12/15 (60%); &gt;80% after c1
mos= nr; 24 mos rfs= 63%, os=81% 
Leukemia fellow at MD Anderson.
(CMC Vellore and AIIMS New Delhi alumnus).Opinionated and adore rationality!Tweets are my own. Science for humanity? 
??????????